Sep 05, 2024 7:30am EDT Rigel Announces First Patient Enrolled in Phase 1b/2 Triplet Therapy Trial of REZLIDHIA® (olutasidenib) in mIDH1 AML
Sep 03, 2024 8:00am EDT Rigel Expands Relationship with Kissei to include REZLIDHIA® (olutasidenib) in Japan, the Republic of Korea and Taiwan
Aug 06, 2024 4:01pm EDT Rigel Reports Second Quarter 2024 Financial Results and Provides Business Update
Jul 30, 2024 8:05am EDT Rigel Announces Conference Call and Webcast to Report Second Quarter 2024 Financial Results and Business Update
Jun 24, 2024 4:05pm EDT Rigel Pharmaceuticals Completes Transfer of GAVRETO® (pralsetinib) New Drug Application
Jun 03, 2024 8:13am EDT Rigel Highlights New Data in Three Poster Presentations at the 2024 ASCO Annual Meeting
